According to our (Global Info Research) latest study, the global Fluorine-18 Radiopharmaceuticals market size was valued at US$ 206 million in 2025 and is forecast to a readjusted size of US$ 322 million by 2032 with a CAGR of 6.5% during review period.
Fluorine-18 radiopharmaceuticals are specialized diagnostic agents utilized primarily in Positron Emission Tomography (PET) imaging. These compounds are synthesized by labeling biologically active molecules—such as glucose analogs, amino acids, or receptor-specific ligands—with the radioisotope Fluorine-18 . Due to its physical properties, including a positron-emitting decay mode and an optimal half-life of approximately 109.8 minutes, F18 is considered the gold standard for clinical molecular imaging. These radiopharmaceuticals enable the non-invasive visualization and quantification of metabolic, physiological, and pathological processes at the cellular level, playing a critical role in the precise diagnosis, staging, and monitoring of oncological, neurological, and cardiovascular diseases.
In 2025, global Fluorine-18 radiopharmaceuticals production reached approximately 2 million GBq, and average price was 100 USD/GBq,with gross margin 65%
The global Fluorine-18 market is experiencing steady expansion, driven primarily by the rising prevalence of chronic diseases such as cancer, Alzheimer’s, and cardiovascular disorders. As the gold standard radionuclide for Positron Emission Tomography (PET) imaging, Fluorine-18 benefits from its 110-minute half-life, which allows for efficient centralized production and distribution. Market growth is further propelled by the adoption of precision medicine, the expansion of cyclotron infrastructure, and the continuous development of novel radiotracers beyond traditional FDG. While North America remains the dominant region due to its advanced healthcare infrastructure and high utilization of PET/CT systems, the Asia-Pacific region is emerging as the fastest-growing market, fueled by significant investments in nuclear medicine and increasing healthcare accessibility. Future market trends emphasize the integration of AI in diagnostic imaging, the rise of "theranostics," and a strategic shift toward localized, hospital-adjacent cyclotron facilities to optimize supply chain efficiency.
Report Scope
This report is a detailed and comprehensive analysis for global Fluorine-18 Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fluorine-18 Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
Global Fluorine-18 Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
Global Fluorine-18 Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (GBq), and average selling prices (US$/GBq), 2021-2032
Global Fluorine-18 Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (GBq), and ASP (US$/GBq), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fluorine-18 Radiopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fluorine-18 Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ANSTO, Rosatom, Eckert & Ziegler, CNNC, Curium Pharma, GE HealthCare, Jubilant Radiopharma, Cardinal Health, IBA, Sumitomo Heavy Industries, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Fluorine-18 Radiopharmaceuticals market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Nucleophilic Labeling
Electrophilic Labeling
Market segment by Functional
Metabolic Tracers
Receptor-Binding Tracers
Amino Acid Transporters
Others
Market segment by Specific Activity
High Specific Activity
Low Specific Activity
Market segment by Application
Medical Imaging
Scientific Research
Major players covered
ANSTO
Rosatom
Eckert & Ziegler
CNNC
Curium Pharma
GE HealthCare
Jubilant Radiopharma
Cardinal Health
IBA
Sumitomo Heavy Industries
Sinotau
Nueclear Healthcare
DC Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Fluorine-18 Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Fluorine-18 Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of Fluorine-18 Radiopharmaceuticals from 2021 to 2026.
Chapter 3, the Fluorine-18 Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Fluorine-18 Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Fluorine-18 Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Fluorine-18 Radiopharmaceuticals.
Chapter 14 and 15, to describe Fluorine-18 Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Fluorine-18 Radiopharmaceuticals. Industry analysis & Market Report on Fluorine-18 Radiopharmaceuticals is a syndicated market report, published as Global Fluorine-18 Radiopharmaceuticals Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Fluorine-18 Radiopharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.